Adagen Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Adagen market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to increased diagnosis of severe combined immunodeficiency (SCID), a rise in healthcare expenditure in developed countries, strong regulatory support for orphan drugs, increased government focus on rare diseases, and the expansion of specialty drug programs.

The projected growth during the forecast period can be attributed to ongoing innovation in drug delivery systems, expanding healthcare infrastructure in emerging economies, increasing accessibility of enzyme replacement therapies, supportive reimbursement policies, and the rising prevalence of genetic disorders. Key trends expected in this period include the introduction of biosimilar enzyme replacement therapies, a focus on reducing production costs, increasing digitalization in healthcare supply chains, collaboration between biotech firms and academic institutions, and advances in long-acting formulations.

The increasing adoption of precision medicine is expected to significantly drive the growth of the adagen market. Precision medicine, which tailors medical treatments to individual genetic profiles, is gaining traction due to advancements in genomic technologies, biomarker availability, artificial intelligence integration, and the growing demand for targeted therapies. Adagen is directly aligned with this shift by providing targeted enzyme replacement therapy for patients with severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency. In 2023, the FDA approved 16 new personalized treatments for rare diseases, reflecting the growing adoption of precision medicine, which will continue to propel the adagen market.

The increasing diagnosis of rare diseases is driving the growth of the adagen market. Rare diseases, which affect fewer than 1 in 2,000 people, are being diagnosed more frequently due to advancements in genetic testing, greater awareness, and better healthcare infrastructure. Adagen contributes to the treatment of SCID, a rare genetic disorder, by offering enzyme replacement therapy, thus supporting early diagnosis and broader research into rare diseases. In the UK alone, over 3.5 million people are affected by rare diseases, which highlights the need for treatments like Adagen to address these conditions, further boosting market demand.

Rising healthcare expenditure is key factor contributing to the growth of the adagen market. As healthcare spending increases due to factors such as medical advancements, aging populations, and rising chronic diseases, the demand for specialized treatments like enzyme replacement therapies is also rising. Adagen's role in treating rare genetic disorders contributes to this rising healthcare expenditure, particularly as the U.S. pharmaceutical industry reached $550 billion in revenue in 2021, with projected spending expected to increase significantly in the coming years. Thus, rising healthcare expenditure supports the continued growth of the Adagen market.

Key player operating in the adagen market are Leadiant Biosciences Inc.

North America was the largest region in the adagen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adagen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the adagen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Adagen is a brand name for pegademase bovine, an enzyme replacement therapy used to treat severe combined immunodeficiency (SCID) caused by adenosine deaminase deficiency. It helps support immune function in individuals with SCID, reducing the risk of life-threatening infections by replenishing the missing enzyme necessary for proper immune system development.

The main product forms of adagen are pre-filled syringes and vials. The pre-filled option provides a ready-to-use syringe or device, ensuring convenience and precise dosing for patients. Adagen is primarily used for clinical indications such as severe combined immunodeficiency (SCID) and other rare genetic disorders. It is utilized across various settings, including hospitals and healthcare institutions, specialty clinics, home healthcare services, and research institutions.

The adagen market research report is one of a series of new reports that provides adagen market statistics, including adagen industry global market size, regional shares, competitors with a adagen market share, detailed adagen market segments, market trends and opportunities, and any further data you may need to thrive in the adagen industry. This adagen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adagen market consists of sales of single-use vials and ready-to-use syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.